Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enliven Therapeutics (ELVN) Other Non Operating Income (2019 - 2025)

Enliven Therapeutics has reported Other Non Operating Income over the past 7 years, most recently at -$2000.0 for Q2 2025.

  • Quarterly results put Other Non Operating Income at -$2000.0 for Q2 2025, down 100.0% from a year ago — trailing twelve months through Mar 2026 was -$2000.0 (up 95.83% YoY), and the annual figure for FY2025 was -$49000.0, down 2350.0%.
  • Other Non Operating Income reached -$2000.0 in Q2 2025 per ELVN's latest filing, up from -$47000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at -$1000.0 in Q1 2024 and bottomed at -$60000.0 in Q1 2021.
  • Median Other Non Operating Income over the past 5 years was -$28000.0 (2021), compared with a mean of -$28500.0.
  • The largest annual shift saw Other Non Operating Income surged 67.27% in 2021 before it tumbled 4600.0% in 2025.
  • Over 5 years, Other Non Operating Income stood at -$57000.0 in 2021, then surged by 33.33% to -$38000.0 in 2022, then surged by 76.32% to -$9000.0 in 2023, then skyrocketed by 88.89% to -$1000.0 in 2024, then crashed by 100.0% to -$2000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for ELVN at -$2000.0 in Q2 2025, -$47000.0 in Q1 2025, and -$1000.0 in Q2 2024.